April 25th 2024
The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Inaccurate Risk Perceptions Lead to Worry and Decreased QOL in Patients with Thyroid Cancer
January 29th 2020The perceptions, which were associated with worry and a decreased quality of life, indicated the need for patient education that is suitable for diverse populations and improved risk communication by physicians.
Hemithyroidectomy Rates Increase Following Guideline Change
September 9th 2019In late 2015, the American Thyroid Association (ATA) changed guideline recommendations trying to rein in overly aggressive treatment of thyroid cancers that are low risk, offering the choice of hemithyroidectomy as an alternative to total thyroidectomy in these patients. In participating hospitals, the rates of hemithyroidectomy went up.